CFN Enterprises Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CFN Enterprises Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.3K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $321.4K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $3.54M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $4.32M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $3.16M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $506.5K | May 17, 2022 |
| FY2017 | Dec 31, 2017 | $24.10M | Mar 27, 2018 |
| FY2017 | Dec 31, 2016 | $23.75M | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | $21.40M | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | $16.46M | Mar 17, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.9K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $295.9K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $514.7K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($2.19M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($381.9K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($30.2K) | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $84 | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | $12.65M | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $15.04M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $15.52M | Mar 27, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.50M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.29M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($15.19M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($9.93M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($12.20M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.59M) | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $8.37M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($11.42M) | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | ($2.42M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($3.85M) | Mar 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.71M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.98M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($13.79M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($8.45M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($12.43M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.23M) | May 17, 2022 |
| FY2020 | Dec 31, 2019 | ($6.01M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.29M) | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | ($1.10M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.65M) | Mar 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $4.17M | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $4.41M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $4.02M | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | $4.63M | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | $2.49M | Mar 17, 2016 |
| FY2014 | Dec 31, 2013 | $1.43M | Mar 19, 2015 |
| FY2013 | Dec 31, 2012 | $933.0K | Mar 25, 2014 |
| FY2012 | Dec 31, 2011 | $499.4K | Mar 7, 2013 |
| FY2011 | Dec 31, 2010 | $418.9K | Mar 29, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.75M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.27M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.63M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.64M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $2.69M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.20M | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.24M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.29M | Jun 15, 2020 |
| FY2016 | Dec 31, 2016 | $8.34M | Mar 22, 2017 |
| FY2016 | Dec 31, 2015 | $9.00M | Mar 22, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($85.6K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $442.8K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($4.98M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.42M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($344.2K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($483.5K) | May 17, 2022 |
| FY2020 | Dec 31, 2019 | ($6.97M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.46M) | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | ($1.47M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $320.9K | Mar 27, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
| FY2020 | Dec 31, 2020 | $6.6K | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $1.8K | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | $36.0K | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $63.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $20.2K | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | $152.1K | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | $598.4K | Mar 17, 2016 |
| FY2014 | Dec 31, 2013 | $216.3K | Mar 19, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.67M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.46M | Apr 15, 2025 |
| FY2021 | Dec 31, 2021 | $6.69M | May 17, 2022 |
| FY2021 | Dec 31, 2020 | $450.5K | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $187.5K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.57M | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | $7.58M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $7.39M | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | $5.06M | Mar 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.94M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $26.50M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $18.89M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $10.04M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $9.09M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.96M | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $861.1K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $16.05M | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | $12.79M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $11.31M | Mar 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2023 | ($13.43M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($9.17M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | ($2.40M) | Apr 11, 2024 |
| FY2021 | Dec 31, 2020 | ($1.51M) | May 17, 2022 |
| FY2021 | Dec 31, 2019 | ($673.6K) | May 17, 2022 |
| FY2020 | Dec 31, 2018 | ($13.47M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($5.22M) | Jun 15, 2020 |
| FY2018 | Dec 31, 2016 | ($3.92M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | ($1.78M) | Mar 27, 2018 |
| FY2016 | Dec 31, 2014 | $667.4K | Mar 22, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($85.77M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($78.95M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($74.42M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($59.00M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($48.83M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($36.38M) | May 17, 2022 |
| FY2020 | Dec 31, 2019 | ($34.72M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($42.96M) | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | ($31.54M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($29.12M) | Mar 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $198.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $373.8K | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $78.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $12.5K | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $170.0K | Apr 11, 2024 |
| FY2022 | Dec 31, 2020 | $160.1K | Apr 17, 2023 |
| FY2020 | Dec 31, 2019 | $107.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $27.3K | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | $166.9K | Apr 16, 2019 |
| FY2018 | Dec 31, 2016 | $1.68M | Apr 16, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.50M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $7.63M | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $7.40M | Apr 11, 2024 |
| FY2022 | Dec 31, 2022 | $4.07M | Apr 17, 2023 |
| FY2020 | Dec 31, 2020 | $913.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | $500.0K | Jun 15, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 17, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 19, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 25, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Mar 7, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Mar 29, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 17, 2016 |
| FY2013 | Dec 31, 2013 | 0 | Mar 25, 2014 |
| FY2013 | Dec 31, 2012 | 0 | Mar 25, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Mar 7, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Mar 29, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.58M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 8.22M | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | 82.21M | Apr 11, 2024 |
| FY2023 | Dec 31, 2022 | 37.61M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | 31.68M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 6.99M | May 17, 2022 |
| FY2020 | Dec 31, 2019 | 99.68M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 66.18M | Jun 15, 2020 |
| FY2018 | Dec 31, 2017 | 65.94M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 63.42M | Mar 27, 2018 |